| SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants F Tea, A Ospina Stella, A Aggarwal, D Ross Darley, D Pilli, D Vitale, ... PLoS medicine 18 (7), e1003656, 2021 | 134 | 2021 |
| Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection A Abayasingam, H Balachandran, D Agapiou, M Hammoud, C Rodrigo, ... Cell reports Medicine 2 (4), 2021 | 76 | 2021 |
| SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern A Aggarwal, AO Stella, G Walker, A Akerman, V Milogiannakis, F Brilot, ... medrxiv, 2021.12. 14.21267772, 2021 | 63 | 2021 |
| Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia A Aggarwal, AO Stella, G Walker, A Akerman, C Esneau, V Milogiannakis, ... Nature Microbiology 7 (6), 896-908, 2022 | 39 | 2022 |
| Emergence and antibody evasion of BQ, BA. 2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level A Akerman, V Milogiannakis, T Jean, C Esneau, MR Silva, T Ison, ... EBioMedicine 90, 2023 | 29 | 2023 |
| Emergence and antibody evasion of BQ A Akerman, V Milogiannakis, T Jean, C Esneau, MR Silva, T Ison, ... BA, 2023 | 8 | 2023 |
| Rapid spread of the SARS-CoV-2 JN. 1 lineage is associated with increased neutralization evasion L Zhang, A Dopfer-Jablonka, A Cossmann, MV Stankov, L Graichen, ... Iscience 27 (6), 2024 | 5 | 2024 |
| TMPRSS2 activation of Omicron lineage Spike glycoproteins is regulated by TMPRSS2 cleavage of ACE2 A Aggarwal, C Fichter, V Milogiannakis, A Akerman, T Ison, MR Silva, ... Biorxiv 1, 2023 | 5 | 2023 |
| Modular lentiviral vectors for highly efficient transgene expression in resting immune cells C Fichter, A Aggarwal, AKH Wong, S McAllery, V Mathivanan, B Hao, ... Viruses 13 (6), 1170, 2021 | 5 | 2021 |
| Emergence and antibody evasion of BQ, BA. 2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine 2023; 90 … A Akerman, V Milogiannakis, T Jean, C Esneau, MR Silva, T Ison, ... DOI, 0 | 5 | |
| SARS-CoV-2 Omicron: Evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv 2021.12. 14.21267772 … A Aggarwal, AO Stella, G Walker, A Akerman, V Milogiannakis, F Brilot, ... | 3 | 2021 |
| Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants A Aggarwal, A Stella, A Akerman, G Walker, V Milogiannakis, S McAllery, ... | 2 | 2022 |
| Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic A Akerman, C Fichter, V Milogiannakis, C Esneau, MR Silva, T Ison, ... medRxiv, 2024 | 1 | 2024 |
| Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic. A Ackerman, C Fichter, T Ison, C Esneau, V Milogiannakis, M Ruiz Silva, ... medRxiv, 2024.04. 18.24305862, 2024 | | 2024 |
| Development of Novel Transient Delivery Systems for Gene Therapy C Fichter UNSW Sydney, 2023 | | 2023 |
Anupriya AggarwalUniversity of New South WalesVerified email at kirby.unsw.edu.au
